


Supplemental Online Content

Satukijchai C, Mariano R, Messina S, et al. Factors associated with relapse and treatment of myelin oligodendrocyte glycoprotein antibody–associated disease in the United Kingdom. *JAMA Netw Open*. 2022;5(1):e2142780.
doi:10.1001/jamanetworkopen.2021.42780

eFigure. Clinical Phenotype in Relapsing Disease by Age Group
eTable 1. Clinical Presentation at Onset in ADEM, Brain, and BS Subgroup
eTable 2. Risk of Relapse by for Sex, Race, and Study Site in Total Cohort
eTable 3. Covariates Included in Treatment Analysis

This supplemental material has been provided by the authors to give readers additional information about their work.

eFigure. Clinical Phenotype in Relapsing Disease by Age Group



Abbreviations: ON, optic neuritis; TM, transverse myelitis; ADEM, acute disseminated encephalomyelitis; BS, Brainstem

^aON+TM either sequentially in any order or simultaneously

^bThose who have 3 or more phenotypes during the course of their disease

eTable 1. Clinical Presentation at Onset in ADEM, Brain, and BS Subgroup

ADEM/Brain/BS	Total cohort					Incident cohort
	Total (n=81)	<12 Years (n=47)	12-18 Years (n=13)	>18-40 Years (n=10)	>40 Years (n=11)	Total (n=52)
ADEM, n(%)	55(62.5)	41(87.2)	9(69.2)	3(30)	2(18.2)	39(75)
ADEM alone, n	43	32	8	2	1	31
ADEM with ^a other presentations, n	12	9	1	1	1	8
Brain without encephalopathy, n(%)	10(12.3)	5(10.6)	2(15.4)	3(30)	0	6(11.5)
Brain without encephalopathy alone, n	6	3	1	2	0	3
Brain without encephalopathy with ^a other presentations, n	4	2	1	1	0	3
Brain stem, n(%)	14(17.2)	1(2.1)	1(7.7)	3(30)	9(81.8)	6(11.5)
Brain stem alone, n	8	1	1	1	5	3
Brainstem with ^a other presentations, n	6	0	0	2	4	3
Cortical, n(%)	2(3.6)	0	0	1(10)	1	2(3.8)
Cortical with simultaneous ON and TM, n	1	0	0	0	1	1
Cortical with meningeal involvement, n	1	0	0	1	0	1

Abbreviations: ADEM, acute disseminated encephalomyelitis, BS; Brainstem
^aother presentations; those including optic neuritis and or transverse myelitis

eTable 2. Risk of Relapse by for Sex, Race, and Study Site in Total Cohort

Clinical Characteristic	N	Log rank, P- value	Cox proportional hazards regression, HR (95%CI), P-value
Sex		0.25	Unadjusted
Female	116		Reference
Male	110		0.81 (0.58-1.16), 0.26
Race		0.10	Unadjusted
Asian total	28		Reference
Black	8		1.55 (0.55-4.35), 0.41
White	204		0.76 (0.42-1.36), 0.35
^a Mixed race or other	6		1.83 (0.65-5.13), 0.25
Study site		0.32	Adjusted with age at onset
Oxford and outreach sites	146		Reference
Liverpool	65		0.79 (0.53-1.17), 0.24
Birmingham Children’s Hospital	32		0.71 (0.39-1.30), 0.27
Evelina Children’s Hospital London	22		0.47 (0.20-1.12), 0.09
Cardiff Wales	11		0.46 (0.14-1.44), 0.18

^aIndividuals with mixed race and other race were those who self-identified as others outside of the categories listed in this table.

eTable 3. Covariates Included in Treatment Analysis

Clinical Characteristic	N	Cox proportional hazards regression, HR (95%CI), P-value		
		Unadjusted	Adjusted	Risk of relapse
Phenotype at onset				
ON	76	2.66(1.01-6.98), 0.047	2.37(0.8-7), 0.120 ^a	↑
TM	37	Reference	Reference ^a	
Phenotype at onset				
No TM	69	Reference	Reference ^a	
Any TM	114	0.41 (0.20-0.82), 0.012	0.47 (0.22-1.0), 0.049 ^a	↓
Age at onset				
>18-40	103	2.10(0.94-4.69), 0.072	2.71 (1.18-6.19), 0.018 ^b	↑
>40	59	Reference	Reference ^b	
Number of relapses prior to IS therapy	Significant different among treatment group, $P < .001$			

Abbreviations: ON; Optic neuritis, TM; Transverse myelitis, IS; immunosuppression/immunomodulation

^aAdjusted covariate for phenotype at onset; follow on oral prednisolone

^bAdjusted covariate for age at onset; any TM at onset and Isolated ON at onset